GMP News and Research

RSS

Research collaboration aims to develop new drug for slow-healing chronic wounds

The biotech company Omnio based in Swedish Umeå, and led by researcher Tor Ny at Umeå University, launches a research collaboration with the Canadian pharmaceutical company ProMetic to develop a new drug for slow-healing chronic wounds. The collaboration includes funding for clinical studies of a drug based on the blood plasma protein plasminogen.

15 Nov 2015

Deep, uniform exome coverage in one day

Integrated DNA Technologies (IDT), introduces its new xGen® Exome Research Panel v1.0 for insightful analysis of the human exome via next generation sequencing.

From Integrated DNA Technologies 10 Nov 2015

TxCell reviews its manufacturing strategy to focus on R&D and strategic partnerships - its core, high added value businesses

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it is operating a strategic review that should result in the outsourcing of all existing and future clinical and commercial manufacturing operations to contract manufacturing organizations (CMOs).

15 Oct 2015

Solix Algredients introduces Solasta Astaxanthin to B2B marketplace

Solix Algredients, Inc. has introduced Solasta Astaxanthin to the B2B ingredients marketplace. Solasta is a natural astaxanthin extract produced from the microalga Haematococcus pluvialis, the richest natural source of the antioxidant. Research has shown that algal astaxanthin has superior antioxidant activity compared to other well-known antioxidants.

7 Oct 2015

Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Generex Biotechnology Corporation today announced that it has entered into a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems, LLC (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies.

30 Sep 2015

Cipla enters into definitive agreements to acquire two US-based companies

Cipla, a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients, today announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc.

4 Sep 2015

Ascletis completes US$35 million (RMB 220 million) financing

Ascletis announced today the completion of a US$35 million (RMB 220 million) financing. The investment was led by C-Bridge Capital, joined by Tasly Pharmaceutical and Singapore-based Pavilion Capital. The valuation of the Company before financing was US$300 million.

2 Sep 2015

NYBC, UC Davis Health System partner to manufacture potential stem cell therapies

New York Blood Center today announced a new collaboration with the University of California, Davis, Health System to manufacture specialized lines of stem cells as potential therapies for repair and regeneration of retina, kidney, lung and liver tissue, as well as for the treatment of neurodegenerative disorders such as Parkinson's, Alzheimer's and Huntington's disease.

20 Aug 2015

GMP protein can improve gastrointestinal health by protecting digestive system from pathogens

The protein glycomacropeptide (GMP) is derived from whey, the liquid by-product of the cheese-making process. GMP contains low amounts of the amino acid phenylalanine. Individuals who suffer from phenylketonuria—a metabolic disorder that causes cognitive impairment when phenylalanine level is too high—can use GMP as an alternative protein source. GMP supplementation has also been observed to improve gastrointestinal health by protecting the digestive system from pathogens and by having an anti-inflammatory effect.

20 Aug 2015

China Pharma Holdings revenue decreases 7.4% to $5.7 million in Q2 2015

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended June 30, 2015.

14 Aug 2015

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.

12 Aug 2015

AmpliPhi provides update on cGMP manufacturing facility and investigational bacteriophage cocktail for treating S. aureus

AmpliPhi BioSciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that the Company will give a presentation today at the 21st Biennial Evergreen International Phage Meeting, taking place August 2-7 in Olympia, Wash.

6 Aug 2015

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million.

24 Jul 2015

Quotient Clinical acquires second GMP manufacturing facility, expands pharmaceutical sciences capabilities

Quotient Clinical, the Translational Pharmaceutics Company, has announced a significant expansion of its pharmaceutical sciences capabilities, doubling capacity through the acquisition of a second GMP manufacturing facility and the construction of new formulation development and pharmaceutical analysis laboratories.

14 Jul 2015

CMC Biologics expands North American manufacturing facility with addition of Bioreactor 6Pack facility

CMC Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, announced today that, as part of its global manufacturing capacity expansion strategy, it has completed the expansion of its North American manufacturing facility in Bothell, Washington with the addition of a single-use Bioreactor 6Pack™ facility.

30 Jun 2015

$FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease$

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell’s Investigational New Drug application for the company’s lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease.

30 Jun 2015

SeraCare Life Sciences inks CRADA with NCI to create positive controls for cancer assays

SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute, part of the National Institutes of Health, to create reference materials and positive controls for cancer assays.

26 Jun 2015

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Siemens and BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, have entered into a strategic collaboration.

25 Jun 2015

IDT’s fully licensed MGB Eclipse qPCR probes available for online ordering

Integrated DNA Technologies (IDT), has become the only company to add fully licensed Minor Groove Binder (MGB) Eclipse GMP probes to its online service, enabling quick and efficient ordering.

From Integrated DNA Technologies 25 Jun 2015

TxCell’s pilot manufacturing facility activities put on temporary partial hold

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that it has temporarily put its pilot manufacturing facility activities at Besançon, France on partial hold.

24 Jun 2015